POINT Biopharma

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

To develop and commercialize small molecule drugs that target proteins with large therapeutic opportunities and are differentiated from existing therapies.

To create a healthier, more connected world by developing and commercializing innovative drugs that address urgent needs.

POINT Biopharma has been the recipient of the National Institutes of Health Catalyst and the Maryland Technology Development Corporation Small Business Innovation Research Grants. The company was recognized by the American Society for Cell Biology in 2020 with the “Pioneer in Cellular and Molecular Biology” award for its innovative approaches to drug discovery.